156079-00-4

Basic information

• Product Name: di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate
• Synonyms: di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate
• CAS NO: 156079-00-4
• Molecular Weight: 424.451
• Mol File: 156079-00-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate(CAS DataBase Reference)
• NIST Chemistry Reference: di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate(156079-00-4)
• EPA Substance Registry System: di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate(156079-00-4)

Safety Data

• Hazardous Substances Data: 156079-00-4(Hazardous Substances Data)

Upstream product

• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 32677-01-3 L-glutamic acid di-tert-butyl ester hydrochloride 
• 16874-06-9 di-tert-butyl L-glutamate 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1053264-73-5 2-m-tolylsulfanylcarbonylamino-pentanedioic acid di-tert-butyl ester 
• 224558-82-1 2-(3-amino-phenylsulfanylcarbonylamino)-pentanedioic acid di-tert-butyl ester 
• 1054647-35-6 2-p-tolylsulfanylcarbonylamino-pentanedioic acid di-tert-butyl ester 
• 1138406-45-7 3'-O-[CO-Glu(OtBu)-OtBu]-quercetin 
• 1138406-16-2 4'-O-[CO-Glu(OtBu)-OtBu]-quercetin 
• 879224-87-0 3'-O-(CO-Glu-OH)-quercetin 
• 1025796-30-8 (S)-2-[3-((S)-(5-benzyloxycarbonylamino)-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 1025796-31-9 (S)-2-[3-((S)-5-amino-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 1610414-00-0 C₃₃H₄₅N₇O₁₇S 
• 1610413-98-3 C₃₁H₄₈N₄O₁₁ 
• 1610413-97-2 C₃₄H₅₄N₄O₁₀ 
• 156079-90-2 di-tert-butyl <<<4-amino>phenyl>oxy>carbonyl>-L-glutamate 
• 156078-99-8 di-tert-butyl <<<4-<(2-chloroethyl)<2-(mesyloxy)ethyl>amino>phenyl>oxy>carbonyl>-L-glutamate 
• 156078-98-7 <<<4-<2-<(mesyloxy)ethyl>(2-chloroethyl)amino>phenyl>oxy>carbonyl>-L-glutamic acid 

Relevant articles and documents

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS

The present invention relates to 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.